

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Luly Jay R.</u> (Last) (First) (Middle) C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET (Street) WATERTOWN MA 02472 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ENANTA PHARMACEUTICALS INC [ ENTA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>President and CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) 12/16/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/16/2022		M		16,149	A	\$14.18	789,954	D	
Common Stock	12/16/2022		M		13,851	A	\$14	803,805	D	
Common Stock	12/16/2022		S <sup>(1)</sup>		7,800	D	\$43.59 <sup>(2)</sup>	796,005	D	
Common Stock	12/16/2022		S <sup>(1)</sup>		8,597	D	\$44.54 <sup>(3)</sup>	787,408	D	
Common Stock	12/16/2022		S <sup>(1)</sup>		13,603	D	\$45.49 <sup>(4)</sup>	773,805	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$14.18	12/16/2022		M			16,149	(5)	12/26/2022	Common Stock	16,149	\$0	0	D	
Stock Option (Right to Buy)	\$14	12/16/2022		M			13,851	(6)	03/21/2023	Common Stock	13,851	\$0	27,912	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$43.29 to \$43.99, inclusive.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$44.04 to \$44.93, inclusive.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$45.00 to \$45.85, inclusive.
- 100% of the shares subject to the option are fully vested and exercisable.
- On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable.

**Remarks:**

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4 above.

/s/ Nathaniel S. Gardiner as attorney-in-fact 12/16/2022  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.